Tag: Ocugen

Biopharmaceutical firm Ocugen has achieved a significant clinical development goal just two days before its annual financial report. Company leadership ...

Biotechnology firm Ocugen has bolstered its financial position through a recent capital raise, providing crucial resources as it approaches significant ...

Investors are piling into Ocugen, Inc., driving a significant rally in the biotech firm's share price. The upward momentum is ...

Friday's trading activity for Ocugen presented a market conundrum. While the share price itself declined, a surge in bullish options ...

In a decisive move aligning leadership incentives with corporate goals, Ocugen, Inc. has established a substantial performance-based equity award for ...

Shares of clinical-stage biopharmaceutical company Ocugen saw elevated trading activity on Monday, with volume running 72% above the average. This ...

Ocugen's stock closed at $1.38 on Friday, marking a single-day gain of 5.34%. This advance represents the third consecutive trading ...

The biotechnology firm Ocugen enters the new trading week with positive momentum. Following a multi-day advance, investors are assessing whether ...

Investors in Ocugen, a biotechnology firm focused on genetic treatments for rare eye diseases, were met with unsettling news in ...

Investors in Ocugen are facing a critical test of resolve. The biotech firm's shares have been under persistent downward pressure, ...